Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial

  title={Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial},
  author={Jonathan S. Berman and C M Symonds and Rolfe Birch},

Figures and Tables from this paper

Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine
No tolerance to the benefit of Sativex on pain or sleep, nor need for dosage increases have been noted in safety extension studies of up to four years, wherein 40–50% of subjects attained good or very good sleep quality, a key source of disability in chronic pain syndromes that may contribute to patients' quality of life.
Cannabis-based medicines for chronic neuropathic pain in adults.
To assess the efficacy, tolerability, and safety of cannabis-based medicines (herbal, plant-derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults, randomised, double-blind controlled trials are selected.
The evidence for pharmacological treatment of neuropathic pain
Medical Cannabis for Neuropathic Pain
Although limited by small sample sizes and short duration of study, the evidence appears to support the safety and efficacy of short-term, low-dose cannabis vaporization and oral mucosal delivery for the treatment of neuropathic pain.
Lack of Analgesia by Oral Standardized Cannabis Extract on Acute Inflammatory Pain and Hyperalgesia in Volunteers
The results suggest that cannabinoids are not effective analgesics for the treatment of acute nociceptive pain in humans and point to the development of a hyperalgesic state under cannabinoids.
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Cannabinoids including the cannabidiol/THC buccal spray are effective in treating neuropathic pain in MS, and cannabinoids were superior to placebo at endpoint.
Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study
Dihydrocodeine provided better pain relief than the synthetic cannabinoid nabilone and had slightly fewer side effects, although no major adverse events occurred for either drug.
Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
Although THC and THC/CBD interventions provided a significant improvement in pain intensity and were more likely to provide a 30% reduction in pain, the evidence was of moderate-to-low quality.


Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies
A total of 34 ‘N of 1’ studies were undertaken using this novel therapy for patients with chronic, mainly neuropathic, pain and associated symptoms to explore efficacy, tolerability, safety and dosages of CBME.
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
Cannabis medicinal extracts can improve neurogenic symptoms unresponsive to standard treatments, and unwanted effects are predictable and generally well tolerated.
Pain relief with oral cannabinoids in familial Mediterranean fever
This is the first United Kingdom report of the controlled use of a standardised pharmaceutical preparation of cannabinoids in capsular form and a highly significant reduction in additional analgesic requirements was achieved.
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review
Cannabinoids are no more effective than codeine in controlling pain and have depressant effects on the central nervous system that limit their use, and in acute postoperative pain they should not be used.
The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
The data indicate that cannabinoids may have therapeutic potential in neuropathic pain, and that this effect is mediated through the CB1 receptor.
Cannabis reduces opioid dose in the treatment of chronic non-cancer pain.
Occurrence and treatment of pain after brachial plexus injury.
The occurrence of pain was investigated in 118 patients with posttraumatic brachial plexus injuries and the destruction of deafferented dorsal horns at the level of avulsion could produce pain relief when medical treatment failed.
Treatment of Refractory Pain after Brachial Plexus Avulsion with Dorsal Root Entry Zone Lesions
Long-term follow-up monitoring of patients who underwent the dorsal root entry zone coagulation procedure in the cervical cord indicated that long-lasting satisfactory relief is possible for the majority of individuals, with acceptable morbidity rates.